Vanda Pharmaceuticals Inc VNDA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if VNDA is a good fit for your portfolio.
News
-
Vanda Pharmaceuticals Acquires U.S. and Canadian Rights to PONVORY® (ponesimod), a Selective S1P1R Modulator Approved for Patients with Relapsing Multiple Sclerosis
-
Vanda Pharmaceuticals Shares Rise Premarket on FDA Review of Tradipitant
-
Vanda Pharma Says FDA Accepts New Drug Application for Tradipitant to Treat Gastroparesis
-
Vanda Pharmaceuticals Announces that U.S. Food and Drug Administration Accepts New Drug Application for Tradipitant for the Treatment of Gastroparesis
-
Vanda Pharmaceuticals Announces Participation at November 2023 Investor Conferences
-
Vanda Pharmaceuticals Reports Third Quarter 2023 Financial Results
-
Vanda Pharmaceuticals to Announce Third Quarter 2023 Financial Results on November 8, 2023
-
Vanda Pharmaceuticals Intends to Petition the U.S. Supreme Court in its HETLIOZ® ANDA Litigation
Trading Information
- Previous Close Price
- $3.97
- Day Range
- $3.76–3.97
- 52-Week Range
- $3.30–11.01
- Bid/Ask
- $3.40 / $4.36
- Market Cap
- $216.32 Mil
- Volume/Avg
- 822,078 / 1.2 Mil
Key Statistics
- Price/Earnings (Normalized)
- 16.66
- Price/Sales
- 1.03
- Dividend Yield
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises two products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) and Fanapt for the treatment of schizophrenia. Its other products include VHX-896 and ASO Molecules. The majority of revenue is derived from HETLIOZ product sales.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 290
- Website
- https://www.vandapharma.com
Valuation
|
Metric
|
VNDA
|
|---|---|
Price/Earnings (Normalized) | 16.66 |
Price/Book Value | 0.40 |
Price/Sales | 1.03 |
Price/Cash Flow | 7.04 |
Price/Earnings
VNDA
Financial Strength
|
Metric
|
VNDA
|
|---|---|
Quick Ratio | 6.12 |
Current Ratio | 6.32 |
Interest Coverage | — |
Quick Ratio
VNDA
Profitability
|
Metric
|
VNDA
|
|---|---|
Return on Assets (Normalized) | 3.44% |
Return on Equity (Normalized) | 4.12% |
Return on Invested Capital (Normalized) | 4.04% |
Return on Assets
VNDA
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Cnpr | $431.5 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Jwqtgk | $91.5 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Zsqbdkx | $90.2 Bil | |
SGEN
| Seagen Inc Ordinary Shares | Hzmds | $41.3 Bil | |
MRNA
| Moderna Inc | Wtkd | $30.6 Bil | |
ARGX
| argenx SE ADR | Jjxh | $27.0 Bil | |
BNTX
| BioNTech SE ADR | Bcgzb | $24.6 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Hljvwr | $21.3 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Jrpgpv | $17.5 Bil | |
INCY
| Incyte Corp | Pdxnl | $12.3 Bil |